市場調査レポート

商品コード

1498597

がん治療薬の市場規模、シェア、成長分析、用途別、売れ筋医薬品別、エンドユーザー別、地域別 - 産業予測、2024～2031年

Cancer Therapeutics Market Size, Share, Growth Analysis, By Application, By Top Selling Drugs, By End-User, By Region - Industry Forecast 2024-2031

出版日: 2024年06月18日 | 発行: SkyQuest

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 782,916円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 915,864円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,048,812円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.72円

全表示
概要
目次

概要

サンプル依頼リストに入れる

がん治療薬の市場規模は、2022年に1,366億米ドルとなり、予測期間（2024～2031年）のCAGRは9.1%で、2023年の1,490億2,000万米ドルから、2031年までには2,991億3,000万米ドルに成長する見通しです。

がん治療薬市場は、がん罹患率の増加、医療技術の進歩、早期診断・治療に対する意識の高まり、がんに罹患しやすい高齢化人口の増加などの要因によって力強い成長を遂げています。この成長の鍵となるのは、免疫療法、標的治療、個別化医療などのがん治療における絶え間ない技術革新であり、これらは様々ながん種において患者の転帰と生存率を顕著に向上させています。同時に、製薬業界による多大な研究開発努力により、数多くの新薬が承認され、治療の選択肢が広がっています。また、世界各国の政府やヘルスケア機関も、がん研究への投資を強化し、安価な治療法へのアクセスを改善してきました。しかし、治療費の高騰がアクセシビリティを制限していること、複雑な規制のハードルが薬剤の承認を遅らせていること、がんの不均一性と耐性の複雑さが続いていることなど、課題は依然として残っています。これらの障害を克服するには、効果的ながん治療法を進歩させ、より多くの患者の利益を確保するために、学術界、産業界、規制当局の持続的な協力努力が必要です。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- イタリア
- 英国
- その他欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主要な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

Roche Holding AG（Switzerland）
Novartis AG（Switzerland）
Merck & Co., Inc.（USA）
Pfizer Inc.（US）
AstraZeneca plc（UK）
Bristol Myers Squibb Company（USA）
AbbVie Inc.（USA）
Amgen Inc.（USA）
GlaxoSmithKline plc（United Kingdom）
Eli Lilly and Company
Takeda Pharmaceutical Company Limited（Japan）
Sanofi S.A.（France）
Gilead Sciences, Inc.（USA）
Bayer AG（Germany）
Johnson & Johnson USA
AbilityPharma（Spain）
Adcendo（Denmark）
Beroni Group（Australia）
BioAtla（USA）
Astellas Pharma Inc.（Japan）

Product Code: SQMIG35H2214

Cancer Therapeutics Market size was valued at USD 136.6 Billion in 2022 and is poised to grow from USD 149.02 Billion in 2023 to USD 299.13 Billion by 2031, at a CAGR of 9.1% during the forecast period (2024-2031).

The cancer therapeutics market has been witnessing robust growth driven by factors such as increasing cancer prevalence, advancements in medical technology, heightened awareness of early diagnosis and treatment, and a growing ageing population vulnerable to cancer. Key to this growth is the continual innovation in cancer therapies like immunotherapies, targeted treatments, and personalized medicine, which have notably enhanced patient outcomes and survival rates across various cancer types. Concurrently, significant research and development efforts by the pharmaceutical industry have led to the approval of numerous new drugs, thereby enriching treatment options. Governments and healthcare entities worldwide have also stepped up investments in cancer research and improved access to affordable treatments. However, challenges persist, including high treatment costs limiting accessibility, complex regulatory hurdles delaying drug approvals, and the ongoing complexities of cancer heterogeneity and resistance. Overcoming these obstacles demands sustained collaborative efforts among academia, industry, and regulators to advance effective cancer therapies and ensure broader patient benefit.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Therapeutics Market Segmental Analysis

The cancer therapeutics market is segmented based on application, top-selling drugs, end-user and region. In terms of application, the market is segmented into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head and neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. Based on top-selling drugs, the market is segmented into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and others. Based on end-user, the market is segmented into hospitals, speciality clinics, and cancer and radiation therapy centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Cancer Therapeutics Market

The rising global incidence of cancer is a pivotal factor propelling the expansion of the cancer therapeutics sector. Contributing to this trend are factors like an ageing demographic, shifts in lifestyle, and increased environmental risks, all of which have led to a higher prevalence of diverse cancer types. Consequently, there is an escalating need for innovative and efficient treatment solutions, prompting extensive developments in cancer therapies and consequently boosting market growth.

Restraints in the Cancer Therapeutics Market

The primary obstacle facing the cancer treatment market is its exorbitant costs, particularly associated with advanced therapies like targeted treatments and immunotherapy. These innovative approaches often come with steep price tags, which pose significant barriers to access for patients residing in low-income areas. Moreover, the financial strain imposed by these expenses not only affects individuals but also burdens healthcare systems. Consequently, the escalating costs of cancer treatment impede the market's expansion and adoption of these cutting-edge therapies, potentially limiting their widespread availability and utilization.

Market Trends of the Cancer Therapeutics Market

The expiration of patents on numerous biologics used in cancer therapy has spurred a surge in the production and authorization of biosimilars. These biosimilars present economical alternatives to costly cancer biologics, significantly enhancing patients' ability to obtain treatment. Consequently, they have captured substantial market interest owing to their affordability, driving their widespread adoption and market expansion. Elaborating further, the expiration of patents for various cancer biologics has led to an uptick in the production of biosimilars, which are cheaper alternatives. This shift has democratized access to cancer treatment, benefiting a larger number of patients who previously faced financial barriers. Biosimilars' cost-effectiveness has not only attracted significant attention from healthcare providers but has also spurred growth in the market. As a result, biosimilars are increasingly becoming a preferred choice, not only due to their affordability but also for their role in broadening access to critical therapies across diverse patient populations.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Ecosystem of the Market
Start-up Analysis
Regulatory Landscape
Innovation Matrix
Value Chain Analysis
Pipeline Analysis
Patent Analysis
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Cancer Therapeutics Market by Cancer Type

Market Overview
Blood Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Breast Cancer
Cervical Cancer
Head and Neck Cancer
Glioblastoma
Malignant Meningioma
Mesothelioma
Melanoma
Others

Cancer Therapeutics Market by Therapy Type

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Other Treatment Types

Cancer Therapeutics Market by Top Selling Drugs

Market Overview
Revlimid
Avastin
Herceptin
Rituxan
Opdivo
Gleevec
Velcade
Imbruvica
Ibrance
Zytiga
Alimta
Xtandi
Tarceva
Perjeta
Temodar
Others

Cancer Therapeutics Market by End User

Market Overview
Hospitals
Specialty Clinics
Cancer and Radiation Therapy Centers

Cancer Therapeutics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- Italy
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson USA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbilityPharma (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adcendo (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beroni Group (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioAtla (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

がん治療薬の市場規模、シェア、成長分析、用途別、売れ筋医薬品別、エンドユーザー別、地域別 - 産業予測、2024～2031年

Cancer Therapeutics Market Size, Share, Growth Analysis, By Application, By Top Selling Drugs, By End-User, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主要な市場の考察

がん治療薬市場：がんタイプ別

がん治療薬市場：治療タイプ別

がん治療薬市場：売れ筋医薬品別

がん治療薬市場：エンドユーザー別

がん治療薬市場規模：地域別